Physician profile
Rajiv Malhotra
NPI 1023226743
$186,834.21
in general payments reported to CMS, 2019-2025
26 companies · $42K in 2025
The $42K reported for 2025 was more than what 98% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $7,458 · 2021: $6,910 · 2022: $33K · 2023: $52K · 2024: $30K · 2025: $42K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $69K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $42K · Food and Beverage: $6,668 · Travel and Lodging: $6,659.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $68,734.84 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $41,700.00 |
| Food and Beverage | $6,667.86 |
| Travel and Lodging | $6,658.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $82,824.00 | 2022-2024 | Andexxa |
| Ceribell, INC. | $70,156.03 | 2023-2025 | Pocket Eeg Device, Ceribell Rapid Response Eeg |
| Pfizer INC. | $9,860.17 | 2019-2020 | |
| Conmed Corporation | $8,789.49 | 2019 | |
| Alexion Pharmaceuticals, INC. | $6,861.56 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $3,835.44 | 2019 | |
| Merit Medical Systems INC | $1,743.87 | 2020-2021 | |
| Boston Scientific Corporation | $333.31 | 2024-2025 | Avvigo Guidance System, Watchman, Farapulse |
| Kyowa Kirin, INC. | $331.23 | 2023-2024 | Crysvita |
| W. L. Gore & Associates, INC. | $322.67 | 2024 | Gore Cardioform Septal Occluder |
| Medtronic, INC. | $251.47 | 2024 | Corevalve Evolut R |
| Cook Medical LLC | $249.27 | 2019-2025 | Zilver Ptx |
| Recor Medical INC | $209.11 | 2024 | Paradise Renal Denervation System |
| Siemens Medical Solutions USA, INC. | $151.22 | 2025 | Naeotom Alpha |
| Biosense Webster, INC. | $126.92 | 2024 | Carto 3 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ambu INC. | $118.88 | 2022 | |
| Edwards Lifesciences Corporation | $115.85 | 2023 | Hemosphere |
| Abbott Laboratories | $115.42 | 2025 | Jot Dx |
| Abiomed | $110.90 | 2025 | |
| Heron Therapeutics, INC. | $109.04 | 2025 | Aponvie |
| Portola Pharmaceuticals, LLC | $74.42 | 2020 | |
| Livanova USA, INC. | $70.96 | 2020-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $31.86 | 2020 | |
| Stryker Corporation | $23.96 | 2021 | |
| Zimmer Biomet Holdings, INC. | $17.16 | 2024 | G7 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajiv Malhotra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.